Overview

A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2025-05-30
Target enrollment:
Participant gender:
Summary
This study is a single-arm, open, dose-escalation, and dose-expansion phase I clinical trial of QLS12004 in patients with advanced solid tumors, designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of QLS12004 in subjects with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.